标题
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 15, Issue 4, Pages 234-248
出版商
Springer Nature
发表日期
2018-02-06
DOI
10.1038/nrclinonc.2018.8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
- (2017) Marcela Moisés Maluf Sanguinete et al. IMMUNOLOGICAL INVESTIGATIONS
- STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
- (2017) L.L. Bu et al. JOURNAL OF DENTAL RESEARCH
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis
- (2017) Yan Yang et al. Molecular Cancer
- Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation
- (2017) Yubin Lei et al. Molecular Cancer
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
- (2017) Seth J. Rotz et al. PEDIATRIC BLOOD & CANCER
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia
- (2016) Q. Zhang et al. BLOOD
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
- (2016) M Thorn et al. CANCER GENE THERAPY
- IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
- (2016) G. D. Brooks et al. CANCER RESEARCH
- A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
- (2016) Haihong Zhong et al. CANCER RESEARCH
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
- (2016) Seiichi Odate et al. CLINICAL CANCER RESEARCH
- The biology behind interleukin-6 targeted interventions
- (2016) Xiao Liu et al. CURRENT OPINION IN RHEUMATOLOGY
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
- (2016) Marc Uemura et al. Journal of Hematology & Oncology
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
- (2016) JIAN GAO et al. ONCOLOGY REPORTS
- The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
- (2016) Jessica L. Geiger et al. ORAL ONCOLOGY
- Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
- (2016) Haiyan S. Li et al. Science Signaling
- Role of interleukin-6 in cancer progression and therapeutic resistance
- (2016) Neeraj Kumari et al. TUMOR BIOLOGY
- Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
- (2016) J J Shah et al. Blood Cancer Journal
- Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
- (2016) Uddalak Bharadwaj et al. Oncotarget
- Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer
- (2016) Pradeep Chaluvally-Raghavan et al. Cell Reports
- Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
- (2016) Haiyan S. Li et al. Science Signaling
- IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence
- (2016) Kelsey A. Finkel et al. NEOPLASIA
- Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic
- (2016) Mehrad Tavallai et al. Frontiers in Oncology
- A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
- (2015) E. M. Dijkgraaf et al. ANNALS OF ONCOLOGY
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3 in Esophageal Squamous Cell Carcinoma
- (2015) H.-F. Zhang et al. CLINICAL CANCER RESEARCH
- Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
- (2015) Takuji Okusaka et al. HEPATOLOGY RESEARCH
- Signal Transducer and Activator of Transcription 4 in Liver Diseases
- (2015) Yan Wang et al. International Journal of Biological Sciences
- Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
- (2015) Freya A. Goumas et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
- (2015) Kenshi Suzuki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
- (2015) E Andersson et al. LEUKEMIA
- Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary
- (2015) Nozomu Yanaihara et al. MOLECULAR CARCINOGENESIS
- Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
- (2015) Lara Brambilla et al. Molecular Oncology
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer
- (2015) N D Peyser et al. ONCOGENE
- Targeting JAK kinase in solid tumors: emerging opportunities and challenges
- (2015) M Buchert et al. ONCOGENE
- Emerging strategies for cancer immunoprevention
- (2015) J C Roeser et al. ONCOGENE
- Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma
- (2015) TEPPEI JINNO et al. ONCOLOGY REPORTS
- Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
- (2015) Tomofumi Miura et al. PANCREAS
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
- (2015) Mignon L. Loh et al. PEDIATRIC BLOOD & CANCER
- Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
- (2015) Noah D. Peyser et al. PLoS One
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: A systematic review
- (2015) David G. Watt et al. SURGERY
- The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease
- (2015) Beata Kotowicz et al. TUMOR BIOLOGY
- Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
- (2015) Beatrice Grabner et al. Nature Communications
- Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
- (2015) Can Küçük et al. Nature Communications
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth
- (2015) Malabika Sen et al. NEOPLASIA
- Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
- (2015) Sebastien A. Burel et al. Nucleic Acid Therapeutics
- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
- (2015) Qing Chang et al. NEOPLASIA
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
- (2014) D. Gotthardt et al. BLOOD
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2014) E. Angevin et al. CLINICAL CANCER RESEARCH
- Interleukin-6 and its receptors: A highly regulated and dynamic system
- (2014) Janina Wolf et al. CYTOKINE
- A microRNA 221– and 222–Mediated Feedback Loop Maintains Constitutive Activation of NFκB and STAT3 in Colorectal Cancer Cells
- (2014) Sanhong Liu et al. GASTROENTEROLOGY
- IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L
- (2014) Ilona Kryczek et al. IMMUNITY
- Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
- (2014) YOUNG-AH SUH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
- (2014) Matjaz Rokavec et al. JOURNAL OF CLINICAL INVESTIGATION
- STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells
- (2014) J. W. Austin et al. JOURNAL OF IMMUNOLOGY
- Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain
- (2014) I. L. Campbell et al. JOURNAL OF NEUROSCIENCE
- Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer
- (2014) Lanxi Song et al. Journal of Thoracic Oncology
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Unknown
- (2014) Malabika Sen et al. MOLECULAR MEDICINE
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer
- (2014) V. W. Y. Lui et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
- (2014) Melanie Spitzner et al. Cancers
- Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity
- (2013) D. M. S. Hossain et al. BLOOD
- The role of intratumoral and systemic IL-6 in breast cancer
- (2013) Christine Dethlefsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
- (2013) C Gordziel et al. BRITISH JOURNAL OF CANCER
- MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis
- (2013) W Wu et al. BRITISH JOURNAL OF CANCER
- Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction
- (2013) T Nagasaki et al. BRITISH JOURNAL OF CANCER
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
- (2013) X. Zhang et al. CANCER RESEARCH
- miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma
- (2013) Jun Wei et al. CANCER RESEARCH
- The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo
- (2013) J.-H. Lee et al. CLINICAL CANCER RESEARCH
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Fragment-based drug design and identification of HJC0123 , a novel orally bioavailable STAT3 inhibitor for cancer therapy
- (2013) Haijun Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
- (2013) Z. Kan et al. GENOME RESEARCH
- Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo
- (2013) XIAOLEI ZHANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling
- (2013) Paul Baran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer
- (2013) Yujuan Chen et al. Journal of Breast Cancer
- The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review
- (2013) Antonio Macciò et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
- (2013) K A Dorritie et al. LEUKEMIA
- IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
- (2013) Miao-Fen Chen et al. Molecular Cancer
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma
- (2013) Yunbao Pan et al. PLoS One
- Activation of STAT3 in Human Gastric Cancer Cells via Interleukin (IL)-6-Type Cytokine Signaling Correlates with Clinical Implications
- (2013) Zhengguang Wang et al. PLoS One
- Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma
- (2013) Shasha Li et al. PLoS One
- The role of IL-6 in the radiation response of prostate cancer
- (2013) Chun-Te Wu et al. Radiation Oncology
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer
- (2012) P. L. Ho et al. CANCER RESEARCH
- Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
- (2012) Amir Sonnenblick et al. Clinical & Translational Oncology
- Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
- (2012) M. Sen et al. CLINICAL CANCER RESEARCH
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis
- (2012) Nokitaka Setsu et al. INTERNATIONAL JOURNAL OF CANCER
- Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
- (2012) Chin Hao Chang et al. INTERNATIONAL JOURNAL OF CANCER
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
- (2012) X. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
- (2011) Akihisa Fukuda et al. CANCER CELL
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
- (2011) H. Xin et al. CANCER RESEARCH
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- A Critical Role for STAT3 Transcription Factor Signaling in the Development and Maintenance of Human T Cell Memory
- (2011) Andrea M. Siegel et al. IMMUNITY
- Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors
- (2011) T. Iwata-Kajihara et al. JOURNAL OF IMMUNOLOGY
- Both miR-17-5p and miR-20a Alleviate Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating STAT3 Expression
- (2011) M. Zhang et al. JOURNAL OF IMMUNOLOGY
- Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3
- (2011) Pijus K. Mandal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
- (2011) Zoran Culig et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway
- (2011) A. Yadav et al. MOLECULAR CANCER RESEARCH
- NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
- (2011) S Yoon et al. ONCOGENE
- Dynamics of the STAT3 Transcription Factor: Nuclear Import Dependent on Ran and Importin-β1
- (2011) Velasco Cimica et al. PLoS One
- The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
- (2011) Jayaprakash Karkera et al. PROSTATE
- A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes
- (2010) Xiaolei Zhang et al. BIOCHEMICAL PHARMACOLOGY
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells
- (2010) A. Herrmann et al. CANCER RESEARCH
- Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
- (2010) M. Kujawski et al. CANCER RESEARCH
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Prognostic significance of nuclear pSTAT3 in oral cancer
- (2010) Muzafar A. Macha et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines
- (2010) Wiltrud Lederle et al. INTERNATIONAL JOURNAL OF CANCER
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation
- (2010) Dae Joon Kim et al. PLoS One
- Identification of a New Series of STAT3 Inhibitors by Virtual Screening
- (2010) Kenji Matsuno et al. ACS Medicinal Chemistry Letters
- Rapid and sustained improvement in bone and cartilage turnover markers with the antiâinterleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone
- (2009) Patrick Garnero et al. ARTHRITIS AND RHEUMATISM
- LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
- (2009) B Fuh et al. BRITISH JOURNAL OF CANCER
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma
- (2009) S Takemoto et al. BRITISH JOURNAL OF CANCER
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Stat3 Is a Negative Regulator of Intestinal Tumor Progression in ApcMin Mice
- (2009) Monica Musteanu et al. GASTROENTEROLOGY
- Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
- (2009) Heike Knüpfer et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias
- (2009) Mustafa Benekli et al. JOURNAL OF CLINICAL ONCOLOGY
- Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
- (2009) S. Matsumoto et al. JOURNAL OF IMMUNOLOGY
- The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate
- (2009) R. P. Sahu et al. JNCI-Journal of the National Cancer Institute
- Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis
- (2009) D J Kim et al. ONCOGENE
- Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells
- (2009) N J Sullivan et al. ONCOGENE
- Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
- (2009) M Walter et al. ONCOGENE
- Stat3 Promotes Metastatic Progression of Prostate Cancer
- (2008) Junaid Abdulghani et al. AMERICAN JOURNAL OF PATHOLOGY
- Interleukin-6 predicts recurrence and survival among head and neck cancer patients
- (2008) Sonia A. Duffy et al. CANCER
- Role of Stat3 in suppressing anti-tumor immunity
- (2008) Marcin Kortylewski et al. CURRENT OPINION IN IMMUNOLOGY
- Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
- (2008) Maciej Kujawski et al. JOURNAL OF CLINICAL INVESTIGATION
- Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
- (2008) Yukiyasu Ozawa et al. LEUKEMIA RESEARCH
- Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival
- (2008) Chun-Liang Chen et al. Molecular Cancer
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
- (2008) Sandra Rebouissou et al. NATURE
- Interleukin-6 and cachexia in ApcMin/+ mice
- (2007) Kristen A. Baltgalvis et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More